Massachusetts S895 aims to promote transparency and prevent price gouging of pharmaceutical drug prices.
Massachusetts S895 establishes measures to promote transparency and prevent price gouging of pharmaceutical drug prices. The bill requires pharmaceutical manufacturing companies to provide early notice to the commission if they plan to increase the wholesale acquisition cost of certain drugs. Companies must also file an access and affordability improvement plan if the commission determines that the drug's pricing substantially exceeds its proposed value. The commission can impose civil penalties for non-compliance and requires companies to report on the outcomes of their improvement plans.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.